Repros Therapeutics Inc. (NASDAQ:RPRX) shares shot up 16.7% during trading on Friday . The stock traded as high as $2.20 and last traded at $2.10, with a volume of 1,388,163 shares trading hands. The stock had previously closed at $1.80.

Separately, Zacks Investment Research downgraded Repros Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, July 13th. One analyst has rated the stock with a sell rating and four have issued a hold rating to the company. The stock has a consensus rating of “Hold” and an average target price of $21.50.

The company’s 50-day moving average is $1.70 and its 200-day moving average is $1.51. The stock’s market capitalization is $51.55 million.

Repros Therapeutics (NASDAQ:RPRX) last released its earnings results on Tuesday, May 10th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.22) by $0.02. On average, analysts predict that Repros Therapeutics Inc. will post ($0.75) earnings per share for the current year.

Repros Therapeutics, Inc is a biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders. The Company’s product candidates include Androxal and Proellex. The Company’s primary product candidate Androxal is a single isomer of clomiphene citrate and an orally active proprietary small molecule compound, which is developed for the treatment of secondary hypogonadism in overweight men.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.